Why Drug Repurposing Might Be Biotech's Most Capital-Efficient Strategy

By Paul Michaels

Biotech has entered a new era of financial discipline. The days of easy capital, billion-dollar preclinical valuations, and “platform first, data later” investing have largely disappeared. Today, investors want clinical relevance earlier, development risk reduced, and clearer pathways to commercialization.

That shift may ultimately benefit one of the industry’s most underappreciated strategies: drug repurposing.

For years, repurposing was often viewed as secondary science, less glamorous than novel modalities like CRISPR, gene editing, or AI-designed therapeutics. But in today’s market environment, where capital efficiency increasingly matters as much as scientific ambition, repurposing may represent one of biotech’s most practical paths forward.

The industry may be approaching a point where repurposing is no longer seen as a fallback strategy, but as a fundamentally smarter development model for certain diseases and market conditions.

Innovation Does Not Always Mean Starting From Scratch

The biotech industry often equates innovation with creating entirely new molecular entities. While breakthrough science will always matter, developing a completely novel drug from discovery through approval can require well over a decade and billions of dollars in capital.

That model is becoming increasingly difficult for emerging biotech companies to sustain.

Drug repurposing offers a different approach. Instead of beginning with an unknown molecule and an undefined safety profile, companies can leverage compounds with existing human exposure, known pharmacology, manufacturing history, and regulatory precedent.

This does not eliminate development risk. But it can materially reduce it.

Repurposing also allows companies to redirect capital toward solving the hardest problems in medicine rather than spending years rebuilding foundational knowledge that may already exist.

In many ways, the industry is beginning to recognize that innovation can come not only from inventing new molecules, but also from rethinking how existing therapies are delivered, targeted, or applied to disease biology.

The Economics Of Biotech Have Changed

The current biotech financing environment has forced management teams to become more selective about where they deploy capital.

Programs that once might have advanced with limited data now face far greater scrutiny from investors. Public markets have become less tolerant of long development timelines with uncertain regulatory outcomes. Even venture capital has shifted toward programs capable of generating earlier clinical signals.

This environment favors strategies with:

• Shorter development timelines
• Lower manufacturing complexity
• Existing safety data
• Reduced regulatory uncertainty
• More capital-efficient clinical design

Drug repurposing checks many of those boxes.

That matters because smaller biotech companies are increasingly expected to operate with the discipline of much larger organizations. Investors are no longer rewarding spending alone. They are rewarding execution.

Some Of Medicine’s Biggest Opportunities May Already Exist

One of the most compelling aspects of repurposing is the possibility that clinically meaningful therapies may already exist — but have not yet been fully explored in the right diseases, formulations, or delivery mechanisms.

Historically, many compounds were developed with relatively narrow therapeutic goals. Advances in molecular biology, immunology, and disease pathway analysis are now revealing broader biological effects that may extend far beyond the original indication.

That creates opportunities to revisit older molecules through a far more sophisticated scientific lens.

In some cases, the opportunity may involve reformulation. In others, it may involve alternative routes of administration, combination approaches, or targeting entirely different disease pathways than originally envisioned.

Importantly, this strategy may be particularly relevant in diseases where patients still face significant unmet need despite years of therapeutic innovation.

Regulatory Familiarity Matters

One of biotech’s greatest challenges is uncertainty.

Novel therapies frequently encounter unpredictable clinical, manufacturing, or regulatory hurdles that can significantly extend development timelines and increase costs.

Repurposed drugs may offer partial mitigation of those risks because regulators are often already familiar with the underlying compound’s pharmacology, toxicology, and safety profile.

That familiarity can potentially streamline portions of development, particularly in early-stage clinical work.

In an environment where capital efficiency increasingly influences survival, reducing avoidable uncertainty becomes strategically important.

This is especially true for smaller biotech companies that may not have the resources to absorb repeated clinical setbacks or prolonged development cycles.

Artificial Intelligence Accelerates The Trend

The rise of AI-driven biology may further accelerate drug repurposing.

Historically, identifying new uses for existing compounds relied heavily on observation, academic research, or serendipity. Today, machine learning tools are beginning to uncover biological relationships, pathway interactions, and disease signatures at a scale previously impossible.

That could dramatically expand the universe of repurposing opportunities.

Instead of screening entirely new molecular libraries, future biotech companies may increasingly focus on uncovering overlooked therapeutic applications hiding inside existing pharmacologic databases.

This does not mean novel drug discovery disappears. It will remain essential, particularly for highly complex diseases. But it does suggest the industry may become more balanced between invention and optimization.

Capital Efficiency As A Competitive Advantage

For much of the past decade, biotech rewarded ambitious science regardless of operational burn. That environment has changed.

Today, companies are increasingly evaluated not only on scientific potential, but also on how efficiently they deploy capital toward clinically meaningful milestones.

That shift could fundamentally reshape how emerging biotech companies are built.

Drug repurposing aligns naturally with this environment because it may allow companies to generate human data faster, preserve shareholder value longer, and potentially create partnership opportunities earlier in development.

In many ways, the industry may be entering a phase where efficiency itself becomes a strategic differentiator.

The Industry Needs A Mindset Shift

Biotech has always celebrated disruption. But disruption should not be confused with unnecessary reinvention.

In today’s market, the winners may not simply be the companies with the most complex science. They may be the companies capable of advancing clinically meaningful therapies with the greatest operational efficiency and strategic discipline.

Drug repurposing aligns with that reality.

For emerging biotech companies navigating constrained capital markets, increasing regulatory complexity, and investor demand for near-term execution, repurposing may no longer be viewed as an alternative strategy.

It may become one of the smartest ones.

About The Author:

Paul Michaels is a life sciences executive with more than two decades of experience building strategic partnerships and transactions between Japan and the United States. He has worked with companies including Celgene Corporation, Sumitomo Pharmaceuticals, Teva Pharmaceuticals and Gilead. During nearly 18 years with Inabata & Co. Ltd., he led transactions that advanced pharmaceutical products into the Japanese market.

He co-founded Nobelpharma Co., Ltd. in 2003 and later founded Curative Biotech in 2020, focused on capital-efficient therapeutic development and strategic partnerships. Michaels is also an advocate for Type 1 diabetes research through his involvement with Juvenile Diabetes Research Foundation.